The NIPE technology provides an objective way to assess the nociception/analgesia balance for neonates and young infants, allowing care to be individualized. NIPE offers a continuous assessment of the parasympathetic component of the autonomic nervous system in neonates and young infants. This unique technology is proven to work with extremely premature babies, from around 26 weeks gestation, through to infants up to two years of age. The NIPE is based on the electrocardiogram taken from the patient monitor in use and does not require additional patient sensors.
NIPE technology benefits:
Evaluation of the newborn parasympathetic activity
Evaluation of the newborn autonomic response to prolonged pain
Detect nociception
Evaluate of the state of comfort/ discomfort of the patient
